Development and marketing of high content cytometry devices and tests for diagnosis of infectious diseases based on two platform technologies - Acquisition by Canopy in April 2019
Development of small molecules using an innovative endogenous protective mechanism. Primary focus is the development of a first-in-class oral drug for the treatment of atrial fibrillation